Harvard expert quits FDA panel as furor over Biogen drug grows

Aaron Kesselheim, announced his departure in a letter to FDA Acting Commissioner Janet Woodcock. He is the third committee member to quit in the wake of the highly controversial approval.

from The Boston Globe https://ift.tt/2RMr5Ma
Robert Langreth

Aaron Kesselheim, announced his departure in a letter to FDA Acting Commissioner Janet Woodcock. He is the third committee member to quit in the wake of the highly controversial approval.

https://ift.tt/3zdUik5 June 10, 2021 at 11:40PM